life scienc tool diagnost
earn print ep cheat
earn approach compil quarterli review
cheat sheet across divers coverag univers life scienc tool
diagnost compani includ follow sub-sector anim health
contract servic organ life scienc diagnost dental
 medic suppli chain pleas reach team
copi latest model request
link recent industri research
state cro industri construct ct gov industri metric fund
messag mothership hq visit
cfo fli coop appoint cfo
dental updat drill earn introduc clear align market
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
anim clinic research organizationszoetisztsiqvia holdingsiqvidexx laboratoriesidxxicon plciclrelanco anim elanpra sciencesprahcovetruscvetsyneo synhphibro anim pahccharl river laboratoriescrlpetm expresspetsmedpacemedplif scienc diagnosticsdentaldanaherdhrdentsply-sironaxrayavantoravtralign technologyalgnlabcorp americalhhenri scheinhsicquest diagnosticsdgxpatterson companiespdcofulg geneticsflgtlantheu holdingslnthpharmaceut medic suppli chainamerisourcebergenabccardin cahmckessonmckowen charl martineau pm univers toronto
tabl content
print
print
cardin print
charl river laboratori print
print
print
print
print
print
icon iclr print
print
ia print
labcorp lh print
medpac print
owen minor print
print
print
print
print
syneo health print
zoeti print
print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
oper margin bp driven higher
revenu align scanner
servic well favor foreign exchang rate
oper margin bp driven lower gross
margin higher oper expens growth
includ charg relat invisalign store
oper million vs
oper million vs
million
million
asp insight sequenti increas
asp updat sequenti increas
reflect favor foreign exchang product mix
partial off-set sale promot deferr relat
addit align
due favor impact fx product mix
shift slightli off-set higher promot
guidanc
revenu billion
growth midpoint
capital-expenditure million
capital-expenditure million primarili relat
guidanc
increas align capac facil
total case ship
tax rate
compani data credit suiss estim factset consensu estim million except per share data
figur short interest float
print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
driver strateg relationship grow
custom strength across
driver headwind lash consult
slower growth mwi
driver benefit growth largest
custom strong growth specialti
distribut overal market growth
driver canadian consult oper
incom declin bp y/i larg predic
pharmedium partial off-set volum
oper million vs
million
off-set strong result brazil
expect normal exclud brazil
pharmedium impact oper incom growth
would
pharmedium updat reiter intent resum
oper million vs
limit product memphi facil
commenc commerci distribut near term
facil expect fulli oper
lash fusion roll-out experienc headwind
longer expect roll-out fusion platform
fusion migrat take meaning
longer previous anticip
million
ration pharmedium footprint announc
closur pharmedium smallest least
autom facil plan consolid
two remain open facil
consent decre expect enter agreement
june quarter accomplish may
anticip consent decre allow
oper continu two open compound
guidanc
adj effect tax rate
focu pharmedium strateg review
compani data credit suiss estim factset consensu estim million except per share data
figur short interest float
note consensu estim
cardin print
figur thing rememb cah confer call
thing rememberon year
thing rememberon quarter
driver exist new custom red
driver brand inflat pharma
expect dd growth specialti
driver divestitur china busi
navihealth busi off-set growth
exist custom ex divestitur
fx revenu grew lsd
lower growth driven perform
brand product compensation-rel item
mostli off-set contribut acquisit
oper million y/i
cordi improv manag note cordi
team move sens urgenc drive top-line
growth expect path
profit growth
navihealth june announc sell
stake navihealth busi pe firm cd
net proce potenti use fund share repurchas
among invest view navihealth
better set growth follow pe invest
bp driven impact gener
renew optum litig expens
partial off-set specialti
bp driven perform brand
product market dynam product
oper billion
remain track see improv servic
level fill rate lower back order increas
contract renew extens relationship
contract four year period net
price goe effect juli relationship
guidanc
pharmaceut op earn -hsd ldd
medic op earn -lsd -msd
interest million
focu guidanc gener
trajectori margin
compani data credit suiss estim factset million except per share data
figur pharmaceut price commentari ep guidanc tracker
compani data credit suiss estim million except per share data
cardin oper oper deflat still mid-to-high singl digit trend rel line origin expect brand modest mayb littl bit softer last year trend rel line origin expect non-gaap deflat sell-sid see market environ competit stabl sell side still see competit rel stabl market sell side continu see competit yet stabl environ sell-sid see competit marketplac expect continu also see stabl environ sell side market competit yet stabl brand inflationmid-single-digit high-singl digit continu evalu much valu expectclearli month juli run rate less would normal expect mid singl digitsmid-single-digitmid-single-digitnon-gaap deflationmid-singl digit deflat follow pattern environ competit stabl continu headwind segment see sell-sid deflat remain consist quarter-to-quart see sell-sid deflat remain consist quarter-to-quart brand digit mid-singl digit januari brand inflat came with rang expect price increas came roughli expect non-gaap charl martineau pm univers toronto figur total revenu growth
figur revenu growth segment
figur oper incom growth segment
figur short interest float
note consensu metric
charl river laboratori print
figur thing rememb crl confer call
thing rememberon year
thing rememberon quarter
driver research model demand china
driver research model china insourc
demand across rad
solut niaid contribut bp
driver vivo discoveri strength demand
oncolog capabl bioanalysi
integr better expect
assess discoveri healthi sa
book price strong demand
driver microbi solut biolog
driver robust demand endosaf test
strength endosaf accugenix
continu perform well biolog y/i
capac quarter accommod
unfavor mix bp headwind
fx rm margin fell due rm servic
busi manufactur fell due capac
free million vs million
expand toxicolog medic devic capabl
ad capac accommod demand
biotech pharma client million cash
valu ebitda incl synergi
expect revenu contribut million
integr ahead plan
accugenix grow number biolog
develop dd growth microbi solut
biolog test
oper margin bp yoy driven lower rm
manufactur capac expans well y/i
compens structur chang rm lower due
niaid compens structur chang mpi
free million vs million
citoxlab acquisit deal expand
crl dsa european capabl expect
accret close
guidanc
op margin similar
guidanc
op margin slightli lower y/i
adjust ep mid high-single-digit growth
exclud vc
compani data credit suiss estim factset consensu estim million except per share data
segmentresearch model revenu growth safeti revenu growth revenu growth charl martineau pm univers toronto figur organ sale growth segment
compani data credit suiss estim dsa discoveri safeti assess
mfrg manufactur support rm research model servic
figur free million
figur short interest float
print
figur thing rememb cvet confer call
thing rememberon year
thing rememberon quarter
yet public compani
histor context thu highli limit
normal agenc shift bp
legaci hsah note strength stem
off-set mar vca custom loss
weather rebat reclassif
driver strong perform across
eu market particularli czech
republ poland spain
partial off-set strength brazil
momentum softwar sale
larg due stand cost
oper million
increment invest announc
expect invest million develop next-
gener enterpris cloud pim solut order
improv connect platform
practic add platform
experienc surg new high-qual lead
enrol us lead convers
exceed expect date
guidanc
enrol north america
focu custom shift platform add
traction broadli synergi captur
commentari around competit landscap
compani data credit suiss estim y/i metric incompar due adopt restat date
compani data credit suiss estim factset million except per share data
emerg charl martineau pm univers toronto
figur revenu per practic
figur vet first choic practic platform
figur short interest float
note chwi consensu metric
print
figur thing rememb dhr confer call
thing rememberon year
thing rememberon quarter
oper margin bp y/i includ bp
core oper margin expans combin
higher core growth good execut particularli
across life scienc diagnost platform
free vs
dentalco spin announc announc
intent spin dental unit stand-alone
public compani via revers morri trust
expect ipo follow ge deal
margin increas bp despit fx headwind
free billion vs
ge acquisit februari announc acquir billion
ebitda deal closur expect expect sustain growth ge segment
target million synergi year-thre cog stem valu engin
product initi indirect spend conjunct announc also disclos
expect dental spin execut via ipo like initi stake mid-to-l
inform pleas see note dissect ge biopharma deal
revenu growth
guidanc re-affirmed
non-gaap ep midpoint
revenu growth base busi segment dental lsd
compani data credit suiss estim factset consensu estim million except per share data
organ ebit margin segmentlif acquisit close aug charl martineau pm univers toronto figur revenu growth segment ex-fx
figur organ dental revenu growth compani
figur oper margin segment
figur short interest float
note consensu forward estim
print
figur thing rememb xray confer call
thing rememberon year
thing rememberon quarter
driver strong perform
restor msd row
driver headwind dealer
busi result margin declin lower
sale also neg pressur product mix
advers price particularli imag busi
oper million y/i
digit impress strategi put togeth
comprehens strategi view
begin journey chair-sid dentistri
cross-sel earli cross-sel
work better incentiv salesforc
unifi compani messag custom
driver headwind one less
driver includ million dealer
destock vs million stock
exclud dynam growth
would y/i
ebitda margin bp yoy improv
gross margin base favor product mix
net price portfolio reshap strategi
favor oper leverag bp net
neg impact oper expens
oper million y/i
sbu five product group creat singl
integr suppli chain well announc
reduct headcount progress ahead plan
guidanc
multi-year guidanc
 equip return
growth growth thereaft
oper incom margin
compani data credit suiss estim factset consensu estim million except per share data
dentspli inc sirona dental system inc merger charl martineau pm univers toronto figur intern revenu growth geographi
figur oper margin segment
slightly-msd lsd lsdequipment-lsd msd msd -- posit lsd lsd-msd-hsd hsic int ldentspli healthcar inc sirona dental system inc merger completedon februari charl martineau pm univers toronto figur ev/ebitda
figur short interest float
print
figur thing rememb elan confer call
thing rememberthre quarter
thing rememberon quarter
continu uptak interceptor
credelio vaccin
combin favor yoy
comparison sale remain
gallipr shipment delay
unfavor impact fx
increas demand poultri
animal-onli antibiot
soft swine due asf
combin stock outag
mix combin lower sg expens
due time expens product initi
well cost control measur
free million vs million
declin older gener
off-set increas credelio
resolv gallipr backord
launch european market
growth aqua/poultri
vaccin off-set destock
poultri product
headwind african swine fever
slightli off-set demand/stock
rumensin
favor mix execut cost structur initi
free million vs million
expect asf headwind
million intern sale
compani data credit suiss estim factset consensu estim million except per share data
figur report revenu million
figur report sale segment
growth rate base financi report compani commentari includ result posilac agristat retained/divest
otherwis includ elanco histor result futur project posilac agristat contribut million combin revenu repres anim health revenu
growth rate includ janssen acquisit close chemgen acquisit close late januari
growth includ roughli one month impact chemgen acquisit
growth adjust lohmann acquisit close april estim lohmann contribut result base commentari
lohmann contribut growth growth lohmann contribut disclos estim averag contribut
arriv contribut lohmann
growth includ lohmann impact includ novarti revenu base year disclos novartiss contribut
growth exclud contribut bivi vaccin portfolio
figur quarterli revenu new product
compani data credit suiss estim million new product includ
product launch
averag rumensin entrant bp impact million tripl combo entrant bp million new product bp product bp undisclos acquisit impact janssen food anim vfd gener ractopaminenew product bp companion anim bravectoand nexgard estimate contributionfrom report driven million yoy million yoy bp impact partial off-set pressur food rumensin entrant bp million tripl combo entrant bp million new bp combo bp million new product bp million combo entrant bp million new product bp million optaflexx compound-annual-growth-rate charl martineau pm univers toronto figur quarterli oper margin
compani data credit suiss estim ep reflect pro forma
interest expens million quarter tax expens base tax rate
ep figur reflect tax rate interest expens base elan file
septemb
figur stock chart sinc ipo
figur short interest float
average sinc ipo sinc first day trade price-to-earnings ev/ebitda price price charl martineau pm univers toronto
print
figur thing rememb hsic confer call
thing rememberon year
thing rememberon quarter
driver addit sell day
intern market dental
equip sale servic
driver exist larg custom
increas patient traffic flu season
benefit extra sell day
new custom partial off-set
mild flu season
driver dd growth intern
financi servic dental softwar
financ servic off-set
cost transact cost anim health
busi well lower gross margin north
oper million vs million
expand bp driven cost save initi
strand cost expect achiev modest
strand cost sever million dollar rang
headwind mild flu season expect
slightli softer dental trend
note report revenu growth oper margin commentari remainco basi ex anim health intern growth number includ impact anim health busi
compani data credit suiss estim factset consensu estim million except per share data
compani data credit suiss estim intern sale growth adjust
acquisit fx calendar shift
dental america na consum consum equip equip medic charl martineau pm univers toronto figur ernal sale growth geographi
figur intern sale growth segment
figur oper margin segment
note quarterli growth rate cs estim histor ex anim health
figur short interest float
icon iclr print
figur thing rememb iclr confer call
thing rememberon year
thing rememberon quarter
ex-pf organ growth repres
ex-pf organ growth repres
backlog vs
backlog vs
rfp saw modest mid-singl digit growth rfp
custom concentr revenu
top vs
custom concentr revenu
top vs
net book-to-bil vs
cancel vs histor average
net book-to-bil vs
cancel vs histor average
backlog convers vs
backlog convers vs
headcount vs
oper margin bp yoy oper margin
compar y/i due implement
free million vs million
share buyback million vs million
metric present
headcount vs
oper margin bp yoy oper margin
compar y/i due implement
free million vs million
share buyback million vs million
close januari annual revenu
contribut estim million
revenu billion
impli growth midpoint
adjust ep impli ep
y/i midpoint
metric present
compani data credit suiss estim factset consensu estim million except per share data
compani data credit suiss estim base revenu report
compani data credit suiss estim base revenu report
compar due
figur backlog convers figur prior
compar due
compani data credit suiss estim base revenu book report
compani data credit suiss estim base revenu book report
oper margin reflect implement charl martineau pm univers toronto figur iclr price-to-earnings
figur short interest float
print
figur thing rememb idxx confer call
thing rememberon year
thing rememberon quarter
driver strong growth recur
revenu instrument placement
digit busi primarili volum gain
oper margin bp yoy price gain
volum leverag well
oper expens leverag time invest
oper million y/i
headwind one less sell day
ou consum brexit pull
driver driven intern
consum growth strong doubl digit
us consum refer lab growth
primarili volum gain
oper margin bp yoy driven price
gain oper expens leverag
oper million y/i
guidanc
free cash flow net incom
org revenu support
back brexit consum
compani data credit suiss estim factset million except per share data
figur organ revenu growth segment
anim assay lab management poultri qualiti qualiti anim grouplivestock poultri diagnosticswat qualiti charl martineau pm univers toronto figur organ recur revenu
figur return invest capit
figur short interest float
ia print
figur thing rememb iqv confer call
thing rememberon year
thing rememberon quarter
driver dd cc growth demand real
world evid technolog platform
oce partial off-set analyt
driver greater volum clinic solut
servic clinic trial support servic
net btb vs
backlog convers vs
approach uptak remain healthi btb
excl pass through includ
net btb vs
backlog convers vs
ebitda margin bp yoy bp cc
basi margin expans core busi driven
revenu convers cost takeout off-set greater
share core-en trial
free million vs million
share buyback million vs million
quintiles/im merger complet octob
yoy comparison reflect pro forma
figur assum merger close
exclud defer revenu adjust figur
reflect compar purposesnot
iqvia sinc restat figur reflect
billion
driver cancel north america
reduc volum apac
synergi realiz cost contain
free million vs million
share buyback million vs million
phase trial evalu aducanumab patient
alzheim march million cancel
trial total patient
revenu billion
billion
ebitda million
billion
ep
figur reflect iqv implement
compani data credit suiss estim factset consensu estim million except per share data
compani data credit suiss estim merger im health quintil
complet octob growth rate base pro forma figur
assum merger took effect growth rate maintain basi
year growth rate calcul use restat figur accord
compani data credit suiss estim growth rate assum merger
quintil im health took place base growth
rate calcul use restat figur accord
iqvia net btb convers backlog revenu yoytechnolog analyt develop solut sale medic charl martineau pm univers toronto figur cc revenu growth segment
averageiqv histor btb consid healthi prior compar due oper margin reflect merger quintil im healthprior oper margin reflect implement charl martineau pm univers toronto figur free million
figur short interest float
labcorp lh print
figur thing rememb lh confer call
thing rememberon year
thing rememberon quarter
fx bp partial off-set
neg impact pama
quarterli net btb
vs
fx bp
oper margin bp yoy driven
implement pama mix impact
acquisit chiltern partial off-set organ
revenu growth launchpad save
oper million
walgreen relationship continu enhanc patient
conveni engag particularli
expans strateg collabor walgreen
open addit site florida
activ network prompt compani take
certain system offlin lead disrupt
servic requir week recoveri oper
return normal earn call
driver neg impact
divestitur bp fx bp
day partial off-set organ growth
acquisit
driver lower pass-through revenu
geograph mix fx exclud
line guidanc
due pama-rel lower price higher
personnel cost partial off-set demand
oper million y/i
contract chang updat januari mark
initi open horizon aetna
contract lh pleas perform
experienc declin januari horizon
volum stabil
envigo deal highlight strateg
financi attract deal cro unit
expect accret envigo add biotech
experi capac sa covanc
guidanc
lcd growth
focu updat contract
pln pama appeal walgreen partnership
 prospect lead lab consolid
compani data credit suiss estim y/i metric incompar due adopt restat date
compani data credit suiss estim factset million except per share
drug book new order restat implement therefor charl martineau pm univers toronto
figur ttm book trend
figur adjust oper incom growth segment
figur net debt ebitda
restat implement therefor charl martineau pm univers toronto figur lh ev/ebitda
figur short interest float
medpac print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
oper margin bp y/i primarili driven
increas oper leverag driven peak
oper capac partial off-set higher
increas headcount line medp plan
margin also affect higher reimburs
pocket expens
oper million vs
oper million vs
million
million
quarterli takeaway book rel
includ oncolog metabol cardiovascular avai
addit small mid-siz biotech repres
roughli medp revenu deriv
mid-siz pharma larg pharma
-- revenu report
within singl revenu line item relat expens
present within direct cost breaks-out
direct cost separ cost associ
reimburs out-of-pocket expens fee paid
investig although time differ
cost incur
associ revenu recogn
healthi net book-to-bil
net new busi step million
backlog convers improv slightli
sequenti basi vs
broader cro commentari management note
recoveri also highlight elev
cancel histor level
guidanc
adjust effect tax rate
compani data credit suiss estim factset consensu estim million except per share data
convers compar due charl martineau pm univers toronto figur oper margin prior
compar due
compar due book-to-billttm backlogbacklog convers charl martineau pm univers toronto figur price-to-earnings
figur short interest float
owen minor print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
driver includ million sale byram
oper margin bp yoy driven higher gross
profit margin bp larg off-set sg growth
oper million vs
million
driver byram strength growth manufactur
solut off-set continu declin
oper margin bp yoy driven higher
gross profit margin bp off-set
oper million vs
million
expect alreadi major
contract acceler byram growth
program underway experienc higher
expect turnov time onboard new
began role march note
spent first day meet custom
custom servic see posit trend
custom servic metric
saw sequenti improv product
guidanc
compani data credit suiss estim factset consensu estim million except per share data
compani data credit suiss estim chart exclud interseg
figur net debt ebitda
figur return invest capit
figur short interest float
print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
oper margin bp yoy driven gross
margin bp yoy due increas promot
activ intensifi competit
competit led discount product drive
declin gross margin bp
custom acq cost million higher
oper million vs
million
driven heighten competition/high ad spend
oper million vs
million
guidanc plan continu price
aggress discount promot well
increas advertis
compani data credit suiss estim factset consensu estim million except per share data
compani data credit suiss estim million
figur short interest float
print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
mfa increas sale
cattl combin favor season
demand benefit recent
intern us dairi
intern partial off-set moder us
growth due diseas pressur
segment breakdown sale growth
anim off-set domest sale
volum growth vaccin also outpac
favor product mix improv manufactur
apac latam partial off-set fx
dairi market combin lower poultri
demand due purchas time
vaccin loss domest
distribut agreement weaker econom
condit certain intern market
segment breakdown volum growth
apac partial off-set lower domest demand
poultri swine sector
slightli off-set increas
growth person care product
mix higher manufactur cost anim health
combin reduc volum miner nutrit
oper million vs
oper million vs
million
million
guidanc lower end
revenu ebitda ep guidanc rang
dairi market challeng
anim health million midpoint
focu ep guidanc cs estimate
compani data credit suiss estim factset consensu estim million except per share data
figur oper margin segment
figur short interest float
print
figur thing rememb confer call
thing rememberon year
thing rememberon quarter
oper margin bp yoy oper margin
compar y/i due implement
oper million y/i
vs million
figur basi
oper margin bp yoy driven
favor fx rate partial off-set increas labor
oper million vs
cro metric begin backlog billion new
million
busi author million cancel
million million total servic revenu
end backlog billion
cro metric begin backlog billion new
busi author million cancel
million million total servic
revenu end backlog billion
guidanc re-affirmed
compani data credit suiss estim factset consensu estim million except per share data
figur quarterli net book-to-bil prior
compar due
figur short interest float
print
figur thing rememb dgx confer call
thing rememberon year
thing rememberon quarter
driver larg attribut acquisit
partial off-set pama headwind
vitamin hepat rx drug monitor
driver strong volum growth favor
weather bp partial off-set pama-
oper margin bp yoy driven declin
sg bp partial off-set gross margin
contract bp
oper million y/i
pama updat us district court judg dismiss
lawsuit request implement delay pama
ground jurisdict agre lawsuit
rais import question methodolog
relationship ahead begin
contract jan proactiv
reach physician educ
oper margin bp yoy driven one less
sale day quarter higher reimburs
pressur higher patient concess bp
oper million
prefer lab network pleas
two brand quest amierpath name
prefer provid emphas payor
remain focus drive better manag
 pipelin follow nine deal
contribut growth view
pipelin remain strong sever convers
guidanc
adj ep greater provid
provid oper billion
focu updat contract
transit pama appeal retail relationship
prospect lead lab consolid
compani data credit suiss estim y/i metric incompar due adopt restat date
compani data credit suiss estim factset million except per share data
figur return invest capit
figur net debt ebitda
figur short interest float
syneo health print
figur thing rememb synh confer call
thing rememberon year
thing rememberon quarter
net book-to-bil vs
backlog burn vs
fuel cross sell commerci new
prefer provid full servic oncolog
portfolio top pharma compani
net new busi million
net book-to-bil vs
backlog burn compar
driver maintain leadership small-
to-mids market experienc
strength across custom segment
net book-to-bil vs
driver commerci growth subdu
ebitda margin bp yoy compar
prior period given implement
oper million vs
million
commerci innov solut group
address specif custom commerci need
rose y/i post averag book-to-
bill healthi baselin
across backlog convers averag
compar
backlog burn vs
driver greater strength variou
geographi specif asia
abil continu drive robust growth
strong net award due traction
syneo one kinaps
ebitda margin bp yoy due slightli
elev mix increment commerci
oper million vs
million
intern control weak note
still work remedi materi weak
guidanc
focu commerci revenu momentum
sec investig synh intern control
well biotech fund rfp flow commentari
compani data credit suiss estim factset million except per share data
figur clinic book trend
compar due
syneo book covers book new businessnet book charl martineau pm univers toronto figur ebit margin trajectori
figur short interest float
zoeti print
figur thing rememb ztss confer call
thing rememberon year
thing rememberon quarter
driver apoquel contribut bp
bp cytopoint bp growth
vaccin china
driver led poultri swine partial
off-set declin cattl poultri
benefit new portfolio altern
weak dairi price lower
sale partial offset
driver strong perform cattl
increas sale vaccin driven
higher beef price increas
penetr brazil posit growth
sheep
oper margin bp yoy benefit cost
improv achiev effici
free million vs million
share buyback million vs million
bp growth cytopoint
driver declin cattl
swine time medic
feed addit dairi headwind
driver declin african
impact abaxi million revenu bp
total sale growth
free million vs million
share buyback million vs million
cog revenu
stock performanceconsensu ep yr mo mo charl martineau pm univers toronto figur credit suiss vs consensu mm except per share amount
compani data credit suiss estim factset consensu estim ztss account calendar four fewer intern day compar headwind growth
million except per share data
segmentu companion companion revenu ex-fx yoyu companion companion charl martineau pm univers toronto figur oper revenu growth
figur free million
figur share repurchas million
figur short interest float
compani mention price
labcorp america lh
